ATAI Investor Presentation Deck

SUMMARY OWNERSHIP 22.5%¹ PRODUCT PHARMA- COLOGY PRODUCT FEATURES INDICATIONS CURRENT STATUS INTELLECTUAL PROPERTY HIGHLIGHT Oral Psilocybin (COMP360) 5-HT2A-R agonist Rapid onset, potential for sustained efficacy after single dose Primary: Treatment Resistant Depression, Anorexia Nervosa Potential: Major Depressive Disorder, Autism, Bipolar Disorder, Chronic Cluster Headache COMP360 Phase 3 (TRD) program expected to commence in 4Q 2022 COMP 360 Phase 2 (Anorexia) trial launched Proprietary formulation of synthetic psilocybin, COMP360 COMP360 demonstrated efficacy in reducing depressive symptom severity with rapid and durable response in Phase 2b study COMP360 Phase 2b trial showed a rapid, sustained reduction in depressive symptoms PRIOR EVIDENCE IN HUMANS (COMP360 PHASE 2B) Least squares mean change from baseline in MADRS total score O -8 -10 -12 -14 -16 233 treatment resistant depression patients with depression symptoms Day 1 Day 2 -COMP360 25mg Week 1 Week 3 --COMP360 10mg Week 3:25mg Diff = -6.6, p value = <0.001 vs 1mg 10mg Diff = -2.5, p value = 0.184 * = statistically significant treatment difference vs 1mg at visit Week 6 Week 9 COMP360 1mg Week 12 12 Source: Schedule 13D filed with the SEC as of November 29th, 2021 Note: MADRS = Montgomery-Åsberg Depression Rating Scale;; COMP360 = a proprietary high-purity, polymorphic crystalline formulation of psilocybin; In COMPASS's model of psilocybin therapy, COMP360 is administered in conjunction with psychological support from specially trained therapists. (1) Ownership percentage as of June 30th, 2022

View entire presentation